Research Analysts Set Expectations for DWTX Q1 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Dogwood Therapeutics in a report released on Tuesday, May 19th. HC Wainwright analyst S. Lee forecasts that the company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS and Q4 2027 earnings at ($0.15) EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07.

Separately, Weiss Ratings lowered shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Stock Performance

Shares of Dogwood Therapeutics stock opened at $1.85 on Wednesday. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50. The company has a market cap of $62.22 million, a P/E ratio of -0.17 and a beta of 1.68. The firm has a fifty day moving average of $2.05 and a two-hundred day moving average of $3.56.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 9.05% of the stock is owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.